<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03531255</url>
  </required_header>
  <id_info>
    <org_study_id>APL2-307</org_study_id>
    <nct_id>NCT03531255</nct_id>
  </id_info>
  <brief_title>Multi-center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)</brief_title>
  <official_title>A Phase III, Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apellis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Open Label, Non-Randomized, Multi-Center Extension Study for ongoing and planned
      Phase IB, Phase II, and Phase III studies with APL-2 in subjects with PNH.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 7, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of hematologic treatment-emergent adverse events</measure>
    <time_frame>48 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 48 weeks in hemoglobin levels (g/dL)</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>PNH</condition>
  <arm_group>
    <arm_group_label>APL-2 1,080mg twice weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,080mg APL-2 will be administered subcutaneously twice weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APL-2 1,080mg every three days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,080mg APL-2 will be administered subcutaneously every three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APL-2 1,080mg twice weekly or every three days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,080mg APL-2 will be administered subcutaneously twice weekly or 1,080mg APL-2 will be administered subcutaneously every three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-2</intervention_name>
    <description>Complement (C3) Inhibitor</description>
    <arm_group_label>APL-2 1,080mg twice weekly</arm_group_label>
    <arm_group_label>APL-2 1,080mg every three days</arm_group_label>
    <arm_group_label>APL-2 1,080mg twice weekly or every three days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with PNH who have participated in an APL-2 clinical trial, and have
             experienced clinical benefit in the opinion of the Investigator.

          2. Willing and able to give written informed consent.

          3. Women of child-bearing potential (WOCBP) must have a negative pregnancy test and must
             agree to use protocol defined methods of contraception for the duration of the study
             and 60 days after their last dose of study drug.

          4. Males must agree to use protocol defined methods of contraception and agree to refrain
             from donating sperm for the duration of the study and 60 days after their last dose of
             study drug.

        Exclusion Criteria:

          1. Subjects who have withdrawn from an APL-2 clinical study

          2. Any condition that could increase the subject's risk by participating in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allen Papazian</last_name>
    <phone>617-977-5709</phone>
    <email>clinicaltrials@apellis.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>May 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

